Blood Cancer Journal最新文献

筛选
英文 中文
Publisher Correction: Patient preferences for intervention in the setting of precursor multiple myeloma. 出版商更正:多发性骨髓瘤前兆患者对干预措施的偏好。
IF 12.9 1区 医学
Blood Cancer Journal Pub Date : 2024-10-21 DOI: 10.1038/s41408-024-01174-9
Catherine R Marinac, Katelyn Downey, Jacqueline Perry, Brittany Fisher-Longden, Timothy R Rebbeck, Urvi A Shah, Elizabeth K O'Donnell, Irene M Ghobrial, Omar Nadeem, Brian L Egleston
{"title":"Publisher Correction: Patient preferences for intervention in the setting of precursor multiple myeloma.","authors":"Catherine R Marinac, Katelyn Downey, Jacqueline Perry, Brittany Fisher-Longden, Timothy R Rebbeck, Urvi A Shah, Elizabeth K O'Donnell, Irene M Ghobrial, Omar Nadeem, Brian L Egleston","doi":"10.1038/s41408-024-01174-9","DOIUrl":"10.1038/s41408-024-01174-9","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":"185"},"PeriodicalIF":12.9,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11493951/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142457300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma 1/2期DREAMM-6试验A臂的结果:贝兰他单抗马福多汀联合来那度胺加地塞米松治疗复发/难治性多发性骨髓瘤患者
IF 12.8 1区 医学
Blood Cancer Journal Pub Date : 2024-10-21 DOI: 10.1038/s41408-024-01155-y
Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi S. Kasinathan, Rachel Rogers, Mehreen Shaikh, Amy Curry, Fernando Carreño, Sumita Roy-Ghanta, Joanna Opalinska, Hang Quach
{"title":"Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma","authors":"Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi S. Kasinathan, Rachel Rogers, Mehreen Shaikh, Amy Curry, Fernando Carreño, Sumita Roy-Ghanta, Joanna Opalinska, Hang Quach","doi":"10.1038/s41408-024-01155-y","DOIUrl":"https://doi.org/10.1038/s41408-024-01155-y","url":null,"abstract":"<figure></figure>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"14 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142451898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Appraising ascorbic acid as a chemoprevention agent for acute myeloid leukaemia using Mendelian Randomisation 利用孟德尔随机法评估抗坏血酸作为急性髓性白血病化学预防剂的效果
IF 12.8 1区 医学
Blood Cancer Journal Pub Date : 2024-10-18 DOI: 10.1038/s41408-024-01168-7
Sina A. Beer, Molly Went, Jessica M. Hislop, Richard Houlston, Martin Kaiser
{"title":"Appraising ascorbic acid as a chemoprevention agent for acute myeloid leukaemia using Mendelian Randomisation","authors":"Sina A. Beer, Molly Went, Jessica M. Hislop, Richard Houlston, Martin Kaiser","doi":"10.1038/s41408-024-01168-7","DOIUrl":"https://doi.org/10.1038/s41408-024-01168-7","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"97 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142448597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study 评估作为 MZL 预后标志的 Ki-67 表达和大细胞含量:一项多中心队列研究
IF 12.8 1区 医学
Blood Cancer Journal Pub Date : 2024-10-18 DOI: 10.1038/s41408-024-01162-z
Natalie S. Grover, Kaitlin Annunzio, Marcus Watkins, Pallawi Torka, Reem Karmali, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Geoffrey Shouse, Adam J. Olszewski, Narendranath Epperla
{"title":"Evaluation of Ki-67 expression and large cell content as prognostic markers in MZL: a multicenter cohort study","authors":"Natalie S. Grover, Kaitlin Annunzio, Marcus Watkins, Pallawi Torka, Reem Karmali, Andrea Anampa-Guzmán, Timothy S. Oh, Heather Reves, Montreh Tavakkoli, Emily Hansinger, Beth Christian, Colin Thomas, Stefan K. Barta, Praveen Ramakrishnan Geethakumari, Nancy L. Bartlett, Geoffrey Shouse, Adam J. Olszewski, Narendranath Epperla","doi":"10.1038/s41408-024-01162-z","DOIUrl":"https://doi.org/10.1038/s41408-024-01162-z","url":null,"abstract":"<p>Marginal zone lymphoma (MZL) can have varied presentations and pathologic features, including high Ki-67 expression ( &gt; 20%) as well as increased numbers of large B cells (LC). However, there are limited data available demonstrating the prognostic significance of these variables in patients with MZL. In this multi-institutional retrospective cohort study of patients with MZL treated at 10 centers, we evaluated the association between the presence of Ki-67 expression and increased LCs on survival and risk of histologic transformation (HT). A total of 785 patients were included (60% with extranodal MZL, 20% with nodal MZL, and 20% with splenic MZL). Among the 440 patients with Ki-67 staining, 22% had high Ki-67 (Ki-67 &gt;20%). The median progression-free survival (PFS) for patients with high Ki-67 was 5.4 years compared to 7.0 years for patients with low Ki-67 (HR = 1.45, 95%CI = 1.03–2.05). Ki-67 &gt; 20% strongly correlated with high LDH level. The risk of HT was higher in patients with increased Ki-67 than those without (5-year risk, 9.8% vs 3.87%, <i>p</i> = 0.01). Twelve percent of patients had LC reported on biopsy with 6% having &gt;10% LC. The presence of LC was associated with high Ki-67 (<i>p</i> &lt; 0.001), but not associated with shorter PFS or overall survival (OS). The cumulative risk for HT was higher in patients with LC compared to those without LC (5-year risk, 9.4% vs 2.9%, <i>p</i> = 0.04). Receipt of anthracycline-based therapy did not impact PFS or OS in either group. Ki-67 staining &gt;20% was a prognostic factor for worse survival and strongly correlated with elevated LDH. Novel therapies should be investigated for their potential ability to overcome the high-risk features in MZL. Our data reinforce the importance of obtaining biopsies at relapse or progression, particularly in patients with baseline high Ki-67 and increased LCs, given their increased risk for HT.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"65 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142448600","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study 年龄对新诊断多发性骨髓瘤治疗利用率的影响:一项全国性回顾性队列研究
IF 12.8 1区 医学
Blood Cancer Journal Pub Date : 2024-10-16 DOI: 10.1038/s41408-024-01164-x
Ghulam Rehman Mohyuddin, Hira Mian, Anastasia Gayowsky, Hsien Seow, Rajshekhar Chakraborty, Gregory R. Pond, Samer Al Hadidi, Alissa Visram
{"title":"Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study","authors":"Ghulam Rehman Mohyuddin, Hira Mian, Anastasia Gayowsky, Hsien Seow, Rajshekhar Chakraborty, Gregory R. Pond, Samer Al Hadidi, Alissa Visram","doi":"10.1038/s41408-024-01164-x","DOIUrl":"https://doi.org/10.1038/s41408-024-01164-x","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"124 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142440368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma 多发性骨髓瘤嵌合抗原受体 T 细胞疗法后的免疫效应细胞相关性小肠结肠炎
IF 12.8 1区 医学
Blood Cancer Journal Pub Date : 2024-10-16 DOI: 10.1038/s41408-024-01167-8
Gliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, Jinming Song, Carlos M. Morán-Segura, Jonathan V. Nguyen, Lazaros Lekakis, Sebastian Fernandez-Pol, Annie N. Samraj, Kikkeri N. Naresh, Mariola Vazquez-Martinez, Rachid C. Baz, Jay Y. Spiegel, Lekha Mikkilineni, John M. Gubatan, Surbhi Sidana, Andre de Menezes Silva Corraes, Nilesh M. Kalariya, Krina K. Patel, Kevin G. Shim, Rafael Fonseca, Christopher Ferreri, Peter M. Voorhees, Shambavi Richard, Cesar Rodriguez Valdes, Sireesha Asoori, Jeffrey L. Wolf, Andrew J. Cowan, Douglas W. Sborov, Frederick L. Locke, Yi Lin, Yinghong Wang, Doris K. Hansen
{"title":"Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma","authors":"Gliceida Galarza Fortuna, Rahul Banerjee, Constanza Savid-Frontera, Jinming Song, Carlos M. Morán-Segura, Jonathan V. Nguyen, Lazaros Lekakis, Sebastian Fernandez-Pol, Annie N. Samraj, Kikkeri N. Naresh, Mariola Vazquez-Martinez, Rachid C. Baz, Jay Y. Spiegel, Lekha Mikkilineni, John M. Gubatan, Surbhi Sidana, Andre de Menezes Silva Corraes, Nilesh M. Kalariya, Krina K. Patel, Kevin G. Shim, Rafael Fonseca, Christopher Ferreri, Peter M. Voorhees, Shambavi Richard, Cesar Rodriguez Valdes, Sireesha Asoori, Jeffrey L. Wolf, Andrew J. Cowan, Douglas W. Sborov, Frederick L. Locke, Yi Lin, Yinghong Wang, Doris K. Hansen","doi":"10.1038/s41408-024-01167-8","DOIUrl":"https://doi.org/10.1038/s41408-024-01167-8","url":null,"abstract":"<p>We report 14 cases of immune effector cell (IEC)-associated enterocolitis following chimeric antigen receptor T-cell (CAR-T) therapy in multiple myeloma, with a 1.2% incidence overall (0.2% for idecabtagene vicleucel and 2.2% for ciltacabtagene autoleucel). Patients developed acute-onset symptoms (typically non-bloody Grade 3+ diarrhea) with negative infectious workup beginning a median of 92.5 days (range: 22–210 days) after CAR-T therapy and a median of 85 days after cytokine release syndrome resolution. Gut biopsies uniformly demonstrated inflammation, including intra-epithelial lymphocytosis and villous blunting. In one case where CAR-specific immunofluorescence stains were available, CAR T-cell presence was confirmed within the lamina propria. Systemic corticosteroids were initiated in 10 patients (71%) a median of 25.5 days following symptom onset, with symptom improvement in 40%. Subsequent infliximab or vedolizumab led to improvement in 50% and 33% of corticosteroid-refractory patients, respectively. Five patients (36%) have died from bowel perforation or treatment-emergent sepsis. In conclusion, IEC-associated enterocolitis is a distinct but rare complication of CAR-T therapy typically beginning 1–3 months after infusion. Thorough diagnostic workup is essential, including evaluation for potential T-cell malignancies. The early use of infliximab or vedolizumab may potentially hasten symptom resolution and lower reliance on high-dose corticosteroids during the post-CAR-T period.</p>","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"3 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142440436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes MYC、BCL2和/或BCL6重排的局限期高级别B细胞淋巴瘤:BCL2重排导致不良预后
IF 12.8 1区 医学
Blood Cancer Journal Pub Date : 2024-10-14 DOI: 10.1038/s41408-024-01148-x
Jennifer K. Lue, Efrat Luttwak, Alfredo Rivas-Delgado, Helen Irawan, Alexander Boardman, Philip C. Caron, Kevin David, Zachary Epstein-Peterson, Lorenzo Falchi, Paola Ghione, Paul Hamlin, Steven M. Horwitz, Andrew M. Intlekofer, William Johnson, Anita Kumar, Alison Moskowitz, Ariela Noy, M. Lia Palomba, Ralphael Steiner, Robert Stuver, Pallawi Torka, Santosha Vardhana, Andrew D. Zelenetz, Heiko Schoder, Brandon Imber, Joachim Yahalom, Yanming Zhang, Pallavi Galera, Ahmet Dogan, Umut Aypar, Gilles Salles
{"title":"Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes","authors":"Jennifer K. Lue, Efrat Luttwak, Alfredo Rivas-Delgado, Helen Irawan, Alexander Boardman, Philip C. Caron, Kevin David, Zachary Epstein-Peterson, Lorenzo Falchi, Paola Ghione, Paul Hamlin, Steven M. Horwitz, Andrew M. Intlekofer, William Johnson, Anita Kumar, Alison Moskowitz, Ariela Noy, M. Lia Palomba, Ralphael Steiner, Robert Stuver, Pallawi Torka, Santosha Vardhana, Andrew D. Zelenetz, Heiko Schoder, Brandon Imber, Joachim Yahalom, Yanming Zhang, Pallavi Galera, Ahmet Dogan, Umut Aypar, Gilles Salles","doi":"10.1038/s41408-024-01148-x","DOIUrl":"https://doi.org/10.1038/s41408-024-01148-x","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"27 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142431359","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy 阿伐替尼治疗侵袭性系统性肥大细胞增多症的克隆动态变化
IF 12.8 1区 医学
Blood Cancer Journal Pub Date : 2024-10-14 DOI: 10.1038/s41408-024-01157-w
Xiaomeng Huang, Anthony D. Pomicter, Jonathan Ahmann, Yi Qiao, Opal S. Chen, Tracy I. George, Nataly Cruz-Rodriguez, Sameer Ahmad Guru, Gabor T. Marth, Michael W. Deininger
{"title":"Clonal dynamics of aggressive systemic mastocytosis on avapritinib therapy","authors":"Xiaomeng Huang, Anthony D. Pomicter, Jonathan Ahmann, Yi Qiao, Opal S. Chen, Tracy I. George, Nataly Cruz-Rodriguez, Sameer Ahmad Guru, Gabor T. Marth, Michael W. Deininger","doi":"10.1038/s41408-024-01157-w","DOIUrl":"https://doi.org/10.1038/s41408-024-01157-w","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"67 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142431358","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Patient preferences for intervention in the setting of precursor multiple myeloma. 患者对先兆多发性骨髓瘤干预措施的偏好。
IF 12.8 1区 医学
Blood Cancer Journal Pub Date : 2024-10-14 DOI: 10.1038/s41408-024-01161-0
Catherine R Marinac,Katelyn Downey,Jacqueline Perry,Brittany Fisher-Longden,Timothy R Rebbeck,Urvi A Shah,Elizabeth K O'Donnell,Irene M Ghobrial,Nadeem Omar,Brian L Egleston
{"title":"Patient preferences for intervention in the setting of precursor multiple myeloma.","authors":"Catherine R Marinac,Katelyn Downey,Jacqueline Perry,Brittany Fisher-Longden,Timothy R Rebbeck,Urvi A Shah,Elizabeth K O'Donnell,Irene M Ghobrial,Nadeem Omar,Brian L Egleston","doi":"10.1038/s41408-024-01161-0","DOIUrl":"https://doi.org/10.1038/s41408-024-01161-0","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"36 1","pages":"175"},"PeriodicalIF":12.8,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142439644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database 来那度胺治疗多发性骨髓瘤患者中的急性淋巴细胞白血病:随机对照试验的安全性荟萃分析与世卫组织药物警戒数据库的回顾性研究相结合
IF 12.8 1区 医学
Blood Cancer Journal Pub Date : 2024-10-14 DOI: 10.1038/s41408-024-01154-z
Pierre-Marie Morice, Sabine Khalife-Hachem, Marion Sassier, Véronique Lelong-Boulouard, Alina Danu, Florence Pasquier, Aline Renneville, Charles Dolladille, Jean-Baptiste Micol
{"title":"Acute lymphoblastic leukemia in patients treated with lenalidomide for multiple myeloma: a safety meta-analysis of randomized controlled trials combined with a retrospective study of the WHO’s pharmacovigilance database","authors":"Pierre-Marie Morice, Sabine Khalife-Hachem, Marion Sassier, Véronique Lelong-Boulouard, Alina Danu, Florence Pasquier, Aline Renneville, Charles Dolladille, Jean-Baptiste Micol","doi":"10.1038/s41408-024-01154-z","DOIUrl":"https://doi.org/10.1038/s41408-024-01154-z","url":null,"abstract":"","PeriodicalId":8989,"journal":{"name":"Blood Cancer Journal","volume":"28 1","pages":""},"PeriodicalIF":12.8,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142431361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信